Literature DB >> 28434782

Dimeric isoxazolyl-1,4-dihydropyridines have enhanced binding at the multi-drug resistance transporter.

Scott A Steiger1, Chun Li2, Donald S Backos3, Philip Reigan3, N R Natale4.   

Abstract

A series of dimeric isoxazolyl-1,4-dihydropyridines (IDHPs) were prepared by click chemistry and examined for their ability to bind the multi-drug resistance transporter (MDR-1), a member of the ATP-binding cassette superfamily (ABC). Eight compounds in the present study exhibited single digit micromolar binding to this efflux transporter. One monomeric IDHP m-Br-1c, possessed submicromolar binding of 510nM at MDR-1. Three of the dimeric IDHPs possessed <1.5µM activity, and 4b and 4c were observed to have superior binding selectivity compared to their corresponding monomers verses the voltage gated calcium channel (VGCC). The dimer with the best combination of activity and selectivity for MDR-1 was analog 4c containing an m-Br phenyl moiety in the 3-position of the isoxazole, and a tether with five ethyleneoxy units, referred to herein as Isoxaquidar. Two important controls, mono-triazole 5 and pyridine 6, also were examined, indicating that the triazole - incorporated as part of the click assembly as a spacer - contributes to MDR-1 binding. Compounds were also assayed at the allosteric site of the mGluR5 receptor, as a GPCR 7TM control, indicating that the p-Br IDHPs 4d, 4e and 4f with tethers of from n=2 to 5 ethylenedioxy units, had sub-micromolar affinities with 4d being the most efficacious at 193nM at mGluR5. The results are interpreted using a docking study using a human ABC as our current working hypothesis, and suggest that the distinct SARs emerging for these three divergent classes of biomolecular targets may be tunable, and amenable to the development of further selectivity.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28434782      PMCID: PMC5813499          DOI: 10.1016/j.bmc.2017.04.008

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  37 in total

1.  Chiral resolution and stereospecificity of 6-phenyl-4-phenylethynyl- 1,4-dihydropyridines as selective A(3) adenosine receptor antagonists.

Authors:  J Jiang; A H Li; S Y Jang; L Chang; N Melman; S Moro; X Ji; E B Lobkovsky; J C Clardy; K A Jacobson
Journal:  J Med Chem       Date:  1999-08-12       Impact factor: 7.446

Review 2.  Structural modifications that alter the P-glycoprotein efflux properties of compounds.

Authors:  Stephen A Hitchcock
Journal:  J Med Chem       Date:  2012-04-16       Impact factor: 7.446

Review 3.  CHARMM: the biomolecular simulation program.

Authors:  B R Brooks; C L Brooks; A D Mackerell; L Nilsson; R J Petrella; B Roux; Y Won; G Archontis; C Bartels; S Boresch; A Caflisch; L Caves; Q Cui; A R Dinner; M Feig; S Fischer; J Gao; M Hodoscek; W Im; K Kuczera; T Lazaridis; J Ma; V Ovchinnikov; E Paci; R W Pastor; C B Post; J Z Pu; M Schaefer; B Tidor; R M Venable; H L Woodcock; X Wu; W Yang; D M York; M Karplus
Journal:  J Comput Chem       Date:  2009-07-30       Impact factor: 3.376

Review 4.  Structural basis for the mechanism of ABC transporters.

Authors:  Konstantinos Beis
Journal:  Biochem Soc Trans       Date:  2015-10       Impact factor: 5.407

5.  Copper(I)-catalyzed synthesis of azoles. DFT study predicts unprecedented reactivity and intermediates.

Authors:  Fahmi Himo; Timothy Lovell; Robert Hilgraf; Vsevolod V Rostovtsev; Louis Noodleman; K Barry Sharpless; Valery V Fokin
Journal:  J Am Chem Soc       Date:  2005-01-12       Impact factor: 15.419

Review 6.  Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome.

Authors:  Douglas D Ross
Journal:  Best Pract Res Clin Haematol       Date:  2004-12       Impact factor: 3.020

7.  Halogen bonds in biological molecules.

Authors:  Pascal Auffinger; Franklin A Hays; Eric Westhof; P Shing Ho
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-19       Impact factor: 11.205

Review 8.  4-isoxazolyl-1,4-dihydropyridines: a tale of two scaffolds.

Authors:  Nicholas R Natale; Scott A Steiger
Journal:  Future Med Chem       Date:  2014-05       Impact factor: 3.808

Review 9.  Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders.

Authors:  P Jeffrey Conn; Craig W Lindsley; Jens Meiler; Colleen M Niswender
Journal:  Nat Rev Drug Discov       Date:  2014-09       Impact factor: 84.694

10.  Inhibition of P-glycoprotein-mediated paclitaxel resistance by reversibly linked quinine homodimers.

Authors:  Marcos M Pires; Dana Emmert; Christine A Hrycyna; Jean Chmielewski
Journal:  Mol Pharmacol       Date:  2008-10-22       Impact factor: 4.436

View more
  3 in total

1.  10-N-heterocylic aryl-isoxazole-amides (AIMs) have robust anti-tumor activity against breast and brain cancer cell lines and useful fluorescence properties.

Authors:  Matthew J Weaver; Sascha Stump; Michael J Campbell; Donald S Backos; Chun Li; Philip Reigan; Earle Adams; Howard D Beall; Nicholas R Natale
Journal:  Bioorg Med Chem       Date:  2020-09-24       Impact factor: 3.641

2.  5-Oxo-hexahydroquinoline and 5-oxo-tetrahydrocyclopentapyridine derivatives as promising antiproliferative agents with potential apoptosis-inducing capacity.

Authors:  Sara Ranjbar; Mehdi Khoshneviszadeh; Marjan Tavakkoli; Ramin Miri; Najmeh Edraki; Omidreza Firuzi
Journal:  Mol Divers       Date:  2021-10-20       Impact factor: 2.943

3.  5-Oxo-hexahydroquinoline Derivatives and Their Tetrahydroquinoline Counterparts as Multidrug Resistance Reversal Agents.

Authors:  Omolbanin Shahraki; Mehdi Khoshneviszadeh; Mojtaba Dehghani; Maryam Mohabbati; Marjan Tavakkoli; Luciano Saso; Najmeh Edraki; Omidreza Firuzi
Journal:  Molecules       Date:  2020-04-16       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.